Alembic Pharmaceuticals Limited has informed the Exchange about Investor Presentation
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals posted Q1 FY26 revenue of INR 17.11 billion, up 10% year-on-year but down 3% sequentially. EBITDA grew 20% YoY to INR 2.88 billion with margin expanding to ~17% (from 15% a year ago), while net profit rose 26% YoY to INR 1.55 billion. US Generics revenue grew 13% YoY to INR 5.23 billion on new launches and market share gains, Ex-US Generics surged 21% to INR 3.28 billion, India Branded business grew 5% to INR 5.99 billion, and API was broadly flat at INR 2.61 billion. R&D spending was 8% of revenue. The company highlighted its US pipeline of 268 cumulative ANDA filings with 167 products already commercialized and 15+ launches planned for FY26.
Strong quarterly earnings with EBITDA margin expansion to 17% and 26% net profit growth reflect healthy operational momentum, likely to support investor sentiment. Robust US pipeline and recently commissioned Indore facility point to future growth visibility, though API pricing pressure remains a watchpoint.